<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00339014</url>
  </required_header>
  <id_info>
    <org_study_id>ZB 201</org_study_id>
    <nct_id>NCT00339014</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Different Combinations of Zonisamide-CR Plus Bupropion-SR to Treat Uncomplicated Obesity</brief_title>
  <official_title>A Dose Parallel, Randomized, Placebo-Controlled, Multicenter Study of the Safety and Efficacy of Multiple Regimens of the Combination of Zonisamide CR Plus Bupropion SR in the Treatment of Subjects With Uncomplicated Obesity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Orexigen Therapeutics, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Orexigen Therapeutics, Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine which of seven combinations of Zonisamide CR and&#xD;
      Bupropion SR gives the best weight loss and is safe and well tolerated for the treatment of&#xD;
      obesity not associated with the complications of obesity such as diabetes. In a previous&#xD;
      study, the combination of zonisamide and bupropion SR was shown to be effective for weight&#xD;
      loss compared to either zonisamide, bupropion SR alone or placebo. It is thought that by&#xD;
      adjusting the doses of each drug, giving zonisamide in a controlled release (CR) form and&#xD;
      increasing the doses more slowly, more weight loss and less side effects can be attained.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Over the past few years, knowledge of the pathways and neural circuits that sense body energy&#xD;
      stores has increased dramatically. In particular, it has been shown that the melanocortin&#xD;
      system, a group of neuronal circuits in the arcuate nucleus of the hypothalamus, is the&#xD;
      &quot;final common pathway&quot; for most energy state signals, and that melanocortin signaling is&#xD;
      necessary for normal control of food intake and energy expenditure. Stimulation of POMC&#xD;
      neurons by serotonergic and dopaminergic agents results in release of α-, β- and γ-MSH&#xD;
      through the action of prohormone convertase-2 with a consequent decrease in appetite.A second&#xD;
      counter-regulatory system that inhibits POMC activation is β-endorphin, which binds to a&#xD;
      mu-opioid receptor (MOP-R) and acts as an auto-inhibitory &quot;brake&quot; on the activity of the&#xD;
      melanocortin circuits. Bupropion is an approved antidepressant that blocks reuptake of&#xD;
      serotonin and dopamine. This stimulates secretion of both α -MSH and β-endorphin. α -MSH&#xD;
      binds to melanocortin receptors which in turn results in appetite suppression and increased&#xD;
      energy expenditure. β-endorphin, however, binds to a mu-opioid receptor (MOP-R) and inhibits&#xD;
      the activity of the melanocortin circuits. Zonisamide has multiple effects that may protect&#xD;
      against seizures, including blockade of sodium channels, and reducing voltage dependent&#xD;
      inward (T type) calcium currents, leading to neuronal stabilization. In addition to these&#xD;
      actions, however, it is known to increase 5-hydroxytryptophan and dopamine levels,&#xD;
      simultaneously stimulating α -MSH release while inhibiting AGRP release. Thus, the&#xD;
      combination of bupropion and zonisamide stimulates the melanocortin system while blocking an&#xD;
      important feedback inhibitory pathway.&#xD;
&#xD;
      The combination of zonisamide 400 mg/day and bupropion SR 300 mg/day has been shown to be&#xD;
      more effective for weight loss than either monotherapy or placebo in subjects with&#xD;
      uncomplicated obesity. The hypothesis for the current trial is that greater efficacy and&#xD;
      improved tolerability can be achieved by adjusting the doses and titration of both bupropion&#xD;
      SR and zonisamide, and by giving zonisamide in a controlled release (CR) formulation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">August 2007</completion_date>
  <primary_completion_date type="Actual">August 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>% change in total body weight as measured between baseline and week 24 (ITT-LOCF analysis)</measure>
    <time_frame>Baseline to week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute change in total body weight in kg.</measure>
    <time_frame>Baseline to week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving &gt; 5% weight loss.</measure>
    <time_frame>Baseline to week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving &gt; 10% weight loss.</measure>
    <time_frame>Baseline to week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving &gt; 5% weight loss at week 24 who maintain response to week 48</measure>
    <time_frame>Baseline to week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in measures of quality of life, sleep quality and sleep quantity</measure>
    <time_frame>Baseline to week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting triglycerides level</measure>
    <time_frame>Baseline to week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fasting blood glucose</measure>
    <time_frame>Baseline to week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in systolic and diastolic blood pressure</measure>
    <time_frame>Baseline to week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in HAMD-17 Maier subscale scores</measure>
    <time_frame>Baseline to week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Brief Assessment of Cognition composite scores</measure>
    <time_frame>Baseline to week 24</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">611</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Zonisamide SR 120 mg/day plus Bupropion SR 280 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Zonisamide SR 120 mg/day plus Bupropion SR 360 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Zonisamide SR 240 mg/day plus Bupropion SR 280 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Zonisamide SR 240 mg/day plus Bupropion SR 360 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Zonisamide SR 360 mg/day plus Bupropion SR 280 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 6</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Zonisamide SR 360 mg/day plus Bupropion SR 360 mg/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 7</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zonisamide CR and Bupropion SR</intervention_name>
    <description>Zonisamide SR and Bupropion SR</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_label>Group 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Identical placebo</description>
    <arm_group_label>Group 7</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have body mass index (BMI) of 30 to 43 kg/m2&#xD;
&#xD;
          -  Free from any other clinically significant illness or disease as determined by medical&#xD;
             history and physical examination&#xD;
&#xD;
          -  Non-smoker and no use of tobacco or nicotine products for at least 6 months prior to&#xD;
             screening&#xD;
&#xD;
          -  Normotensive (systolic &lt;140 mm Hg; diastolic &lt;90 mm Hg). Anti-hypertensive medications&#xD;
             are allowed with the exception of adrenergic blockers, beta-blockers and clonidine.&#xD;
             Medical regimen must be stable for at least 6 weeks&#xD;
&#xD;
          -  LDL cholesterol &lt; 190 mg/dL and triglycerides &lt; 400 mg/dL. Medications for treatment&#xD;
             of dyslipidemia are allowed as long as medical regimen has been stable for at least 6&#xD;
             weeks&#xD;
&#xD;
          -  Negative serum pregnancy test in women with an intact uterus&#xD;
&#xD;
          -  Score &lt; 15 for depression and score &lt; 15 for anxiety on Hospital Anxiety and&#xD;
             Depression Scale (HADS)&#xD;
&#xD;
          -  No clinically significant abnormality on ECG&#xD;
&#xD;
          -  Not on eExcluded concomitant medications&#xD;
&#xD;
          -  If female with intact uterus, be non-lactating, and agree to use effective&#xD;
             contraception throughout the study period and for 30 days after discontinuation of&#xD;
             study drugs.&#xD;
&#xD;
          -  Able to comply with all required study procedures and schedule&#xD;
&#xD;
          -  Able to use and have access to a touch tone telephone and to speak and read English&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Obesity of known endocrine or genetic origin&#xD;
&#xD;
          -  Serious medical condition&#xD;
&#xD;
          -  Serious psychiatric illness&#xD;
&#xD;
          -  Active suicidal ideation; score &gt; 2 on the Mood Assessment questionnaire&#xD;
&#xD;
          -  A response to Bipolar Disorder questions indicating the presence of Bipolar Disorder&#xD;
&#xD;
          -  Type I diabetes mellitus or Type II diabetes mellitus requiring pharmacotherapy&#xD;
&#xD;
          -  History of alcohol or drug abuse, current or within 5 years&#xD;
&#xD;
          -  History of bulimia or anorexia nervosa&#xD;
&#xD;
          -  History of surgical intervention for obesity&#xD;
&#xD;
          -  History of seizure disorder or predisposition to seizures (e.g., history of&#xD;
             cerebrovascular accident, significant head trauma, brain surgery, skull fracture,&#xD;
             subdural hematoma, or alcohol withdrawal or febrile seizures)&#xD;
&#xD;
          -  History of hypersensitivity to sulfonamides (&quot;sulfa&quot;), bupropion, or zonisamide&#xD;
&#xD;
          -  History of nephrolithiasis (renal calculi)&#xD;
&#xD;
          -  History of treatment with bupropion SR (Wellbutrin, Zyban) or zonisamide (Zonegran)&#xD;
             within 12 months&#xD;
&#xD;
          -  Use of drugs, herbs, or dietary supplements known to significantly affect body weight&#xD;
             or participation in a weight loss management program within one month prior to&#xD;
             baseline&#xD;
&#xD;
          -  Loss or gain of more than 4.0 kilos within 3 months&#xD;
&#xD;
          -  Women of child bearing potential not adhering to an acceptable form of contraception&#xD;
&#xD;
          -  Pregnant or breast-feeding women&#xD;
&#xD;
          -  Use of investigational drug, device or procedure within 30 days&#xD;
&#xD;
          -  Participation in any previous clinical trial conducted by Orexigen Therapeutics&#xD;
&#xD;
          -  Planned surgical procedure that can impact the conduct of the study&#xD;
&#xD;
          -  Any condition which in the opinion of the investigator makes the subject unsuitable&#xD;
             for inclusion in this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frank Greenway, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pennington Biomedical Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SelfCenter, PC</name>
      <address>
        <city>Fairhope</city>
        <state>Alabama</state>
        <zip>36532</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA Center for Human Nutrition</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scripps Clinic Del Mar</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Human Nutrition University of Colorado Health Sciences Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>George Washington University Weight Management Program</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CSRA Partners in Health, Inc</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Springfield Diabetes and Endocrine Center</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pennington Biomedical Research Center</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nutrition and Weight Mangement Center Boston Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Nutrition and Metabolic Diseases</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89557</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Weight Control Program</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Nutrition and Preventive Medicine</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MUSC Weight Mnagement Center</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Cooper Institute</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Endocrine Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2008</verification_date>
  <study_first_submitted>June 18, 2006</study_first_submitted>
  <study_first_submitted_qc>June 18, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2006</study_first_posted>
  <last_update_submitted>April 18, 2008</last_update_submitted>
  <last_update_submitted_qc>April 18, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 22, 2008</last_update_posted>
  <responsible_party>
    <name_title>Ronald Landbloom, MD</name_title>
    <organization>Orexigen Therapeutics, Inc</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zonisamide</mesh_term>
    <mesh_term>Bupropion</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

